Abstract
Tamoxifen is a selective estrogen receptor modulator (SERM) that is widely used in the treatment of patients with breast cancer and for chemoprophylaxis in high risk women. Tamoxifen results in a spectrum of abnormalities involving the genital tract, the most significant being an increased incidence of endometrial cancer and uterine sarcoma. This article reviews the effects of tamoxifen on the genital tract and the strengths and weaknesses of various imaging modalities for evaluating the endometrium.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / surgery
-
Cervix Uteri / diagnostic imaging
-
Cervix Uteri / drug effects
-
Chemotherapy, Adjuvant
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Endosonography / methods
-
Female
-
Female Urogenital Diseases / chemically induced*
-
Female Urogenital Diseases / diagnostic imaging*
-
Female Urogenital Diseases / epidemiology
-
Follow-Up Studies
-
Humans
-
Incidence
-
Magnetic Resonance Imaging / methods
-
Middle Aged
-
Ovary / diagnostic imaging
-
Ovary / drug effects
-
Risk Assessment
-
Tamoxifen / adverse effects*
-
Tamoxifen / therapeutic use
-
Vagina / diagnostic imaging
-
Vagina / drug effects
Substances
-
Antineoplastic Agents, Hormonal
-
Tamoxifen